Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Infection
54%
Melioidosis
53%
Diseases
45%
Burkholderia pseudomallei
30%
Scabies
22%
Cohort Effect
20%
Prevalence
20%
Rheumatic Heart Disease
19%
Plasmodium
17%
Randomized Controlled Trial
17%
Malaria Falciparum
16%
Rheumatic Fever
15%
Systematic Review
15%
Plasmodium Vivax Malaria
14%
Public Health
13%
COVID-19
11%
Pathogen
10%
Infectious Disease
10%
Staphylococcus Aureus
10%
Clinical Trial
9%
Pneumococcus Vaccine
9%
Sepsis
9%
Pediatrics
9%
Bloodstream Infection
9%
Observational Study
8%
Glucose 6 Phosphate Dehydrogenase
8%
Meta-Analysis
8%
Oral
8%
Odds Ratio
8%
Antibiotics
8%
Health Care Cost
8%
Clinician
7%
Cohort Analysis
7%
Primary Health Care
7%
Serotype
7%
Plasmodium falciparum
6%
Prospective Study
6%
Skin Infection
6%
Health Care Personnel
6%
Impetigo
6%
Health Service
6%
Cross Sectional Study
5%
Primaquine
5%
Human Immunodeficiency Virus
5%
Aboriginal and Torres Strait Islander
5%
Antibiotic Resistance
5%
Anemia
5%
Parasitemia
5%
Lung
5%
Prospective Cohort Study
5%
Immunology and Microbiology
Infection
100%
Plasmodium vivax
43%
Burkholderia pseudomallei
42%
Plasmodium falciparum
39%
Plasmodium
19%
Prevalence
18%
Plasmodium knowlesi
17%
Cohort Effect
17%
Infectious Agent
16%
Staphylococcus aureus
15%
Parasitemia
14%
Chloroquine
13%
Primaquine
11%
Whole Genome Sequencing
9%
Methicillin-Resistant Staphylococcus Aureus
9%
Burkholderia
9%
Serotype
9%
Susceptibility
8%
Single Nucleotide Polymorphism
8%
Blood Plasma
8%
In Vitro
8%
Streptococcus Group A
8%
Multilocus Sequence Typing
8%
Streptococcus pyogenes
8%
Erythrocyte
7%
Pneumococcal Vaccine
7%
Dynamics
7%
Genetic Variability
7%
Lineages
7%
Antibiotic Resistance
6%
Cladistics
6%
Parasite Clearance
6%
Antimalarial Agent
6%
Zoonotic
5%
Streptococcus pneumonia
5%
Immune Response
5%
Allele
5%
Infectious Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
35%
Infection
32%
Malaria Falciparum
28%
Plasmodium Vivax Malaria
25%
Primaquine
20%
Antimalarial Agent
19%
Plasmodium vivax
18%
Plasmodium falciparum
18%
Randomized Controlled Trial
16%
Melioidosis
15%
Prevalence
14%
Artemisinin
13%
Antivenom
12%
Elimination
12%
Chloroquine
11%
Clinical Trial
11%
Combination Therapy
11%
Plasmodium
10%
Artesunate
10%
Staphylococcus aureus
10%
Bloodstream Infection
9%
Glucose 6 Phosphate Dehydrogenase
9%
Scabies
9%
Pharmacokinetic
9%
Parasitemia
9%
Plasmodium Knowlesi Malaria
8%
Rheumatic Heart Disease
8%
Rheumatic Fever
8%
Recurrent Disease
7%
Antibiotics
7%
Cohort Study
7%
Piperaquine
7%
Anemia
7%
Dihydroartemisinin
7%
Sepsis
6%
Observational Study
6%
Snakebite
5%
Infectious Agent
5%
Bite
5%
Methicillin-Resistant Staphylococcus Aureus
5%
Pneumococcus Vaccine
5%
Artemether Plus Benflumetol
5%
Antibiotic Resistance
5%
Toxic Injury
5%
Burkholderia pseudomallei
5%
Prospective Study
5%
Adverse Event
5%
Glucose 6 Phosphate Dehydrogenase Deficiency
5%